Answers are grounded in this paper and cite their sources.
Background Direct comparative evidence for apalutamide and enzalutamide remains limited. We compared their real-world effectiveness, treatment modification, and safety in metastatic castration-sensitive prostate cancer. Methods We retrospectively analyzed 331 consecutive patients treated with apalutamide (n = 208) or enzalutamide (n = 123). The primary endpoint was time to clinically documented castration-resistant prostate cancer (CRPC), defined by prostate-specific antigen (PSA) and/or radiographic progression in a castrate state. Propensity score matching was the primary comparative analysis, with stabilized inverse probability of treatment weighting (IPTW) and disease-burden-adjusted IPTW as sensitivity analyses. Results Matching yielded 85 pairs, with a maximum post-match absolute standardized mean difference of 0.073. Time to PSA <0.1 ng/ml was similar between groups [hazard ratio (HR) 1.00, 95% confidence interval (CI) 0.66–1.51; P = .996]. Time to clinically documented CRPC was shorter with apalutamide (HR 2.13, 95% CI 1.08–4.19; P = .029), whereas overall survival (OS) was similar (HR 1.30, 95% CI 0.54–3.11; P = .557). Stabilized IPTW reproduced the CRPC association (HR 2.04, 95% CI 1.10–3.75; P = .023), as did IPTW additionally accounting for CHAARTED high-volume and LATITUDE high-risk disease (HR 2.15, 95% CI 1.13–4.08; P = .020). Dose reduction, non-progression-related treatment interruption or discontinuation, and adverse events were more frequent with apalutamide. Conclusions In this retrospective cohort, enzalutamide was associated with longer time to clinically documented CRPC than apalutamide, while deep PSA response and OS were similar. Weighted sensitivity analyses supported the primary association, but residual confounding and limited events preclude causal claims.
No takes yet. Share an insight, caveat, or question.
Ohtani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: